Welcome to our dedicated page for Verastem SEC filings (Ticker: VSTM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Verastem's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Verastem's regulatory disclosures and financial reporting.
Vanguard Capital Management LLC, together with certain affiliates, reports beneficial ownership of Verastem Inc common stock on a Schedule 13G. As of June 30, 2026, Vanguard Capital Management beneficially owned 4,423,544 shares of Verastem Inc common stock, representing 5.03% of the class.
Vanguard Capital Management has sole voting powersole dispositive power
BlackRock, Inc. filed an amended Schedule 13G/A reporting beneficial ownership of common stock of INC (symbol VSTM). BlackRock reports beneficial ownership of 6,187,012 shares of common stock, representing 7.0% of the class as of June 30, 2026.
BlackRock reports sole voting powersole dispositive power
Verastem Inc. is the issuer for a notice covering potential sales of its common stock by Robert Gagnon. The notice lists up to 31,924 shares of common stock to be sold through Jefferies LLC, with an aggregate market value of $188,032.36 and a noted transaction date of July 23, 2026 on NASDAQ.
The shares relate to previously vested restricted stock units and vested stock options granted by Verastem Inc. The filing also lists sales during the prior three months, including two transactions of 20,103 shares each on May 27, 2026 and June 25, 2026, with sale values of $84,835.67 and $70,072.42 respectively.
Polar Capital group reports a 13G/A filing disclosing beneficial ownership in Verastem, Inc. The filing states the group (Polar Capital Holdings plc, Polar Capital LLP and Polar Capital Funds PLC - Biotechnology Fund) beneficially owns 3,700,000 shares, representing 4.80% of Verastem's common stock. The filing cites 77,154,709 shares outstanding as of January 12, 2026 as the basis for the percentage. Signatures show Nicholas Farren, Chief Operating Officer, executed joint filing statements on behalf of the entities.
Verastem Inc. submitted a Form 144 notice reporting a proposed resale of 21,492 shares of Common Stock originally issued as vested Restricted Stock Units dated 12/15/2021. The filing lists Robert Gagnon as the seller and shows 20,103 shares sold in the past three months.
Verastem, Inc. President and CEO Dan Paterson reported an open-market sale of 20,871 shares of common stock at $4.18 per share. According to the footnote, this sale was made to satisfy statutory withholding requirements related to the vesting of restricted stock units, rather than a discretionary trade. Following the transaction, he directly owns 591,242 shares of Verastem common stock.
Verastem, Inc. Chief Financial Officer Daniel Calkins reported selling 4,089 shares of common stock. The transactions on June 22, 2026 consisted of open-market sales of 57 shares at $4.13 per share and 4,032 shares at $4.18 per share.
According to the footnote, these sales were made to satisfy statutory withholding requirements tied to the vesting of restricted stock units, meaning they were compensation-related rather than discretionary portfolio trades.
Verastem, Inc. reported detailed preliminary data for VS-7375, its investigational oral KRAS G12D (ON/OFF) inhibitor, from the ongoing Phase 1/2 TARGET-D 101 trial in advanced solid tumors. Doses from 400 mg to 900 mg once daily showed anti-tumor activity in metastatic pancreatic ductal adenocarcinoma, metastatic colorectal cancer and advanced non-small cell lung cancer, both as monotherapy and in combinations.
At the June 12, 2026 cutoff, VS-7375 demonstrated a favorable safety profile at 600 mg once daily in 57 patients and 900 mg once daily in 25 patients, with mostly low-grade gastrointestinal side effects and limited Grade 3 events. In metastatic pancreatic cancer, 93% of 14 patients at 900 mg once daily achieved more than a 50% reduction in the tumor marker CA19-9, and individual case examples showed rapid, deep radiographic responses.
More than 150 patients have been enrolled across dose-escalation and expansion cohorts. Verastem plans to complete enrollment in three Phase 2 TARGET-D trials by the end of 2026 and to enroll the first patients in three Phase 3 pivotal trials in first-line pancreatic, colorectal and lung cancer by the first half of 2027. The company also announced its intent to enter into a collaboration with Erasca, Inc. to evaluate VS-7375 in combination with ERAS-0015, initially in preclinical models and potentially in future clinical trials.
Verastem, Inc. filed a Form 144 notifying a proposed sale of 20,871 shares of Common Stock. The filing shows a prior sale of 806 shares on 05/04/2026 and lists 87,873,639 shares outstanding as of 06/22/2026.
Verastem Oncology reported updated early-stage results from its RAMP 205 Phase 1b/2a trial in first-line metastatic pancreatic ductal adenocarcinoma. In 29 patients treated at the recommended Phase 2 dose with avutometinib plus defactinib and standard chemotherapy, 90% had metastatic disease at diagnosis.
As of a June 5, 2026 data cutoff and 9.8 months median follow-up, the combination showed an 86% overall survival rate at 6 months, a 68% progression-free survival rate at 6 months, and a confirmed objective response rate of 52% (15 of 29 patients). Most patients (83%) experienced tumor shrinkage, nine remained on treatment, and no new safety signals were observed.
The company also began dosing the first patient in TARGET-D 201, a Phase 2 registration-directed trial of VS-7375, an investigational oral KRAS G12D inhibitor, given at 900 mg daily as monotherapy and with full-dose cetuximab in second-line metastatic pancreatic cancer.